Map a drug-technology landscape and patent strategy

Built for pharma R&D strategy, licensing, and due diligence

The workflow

The 6-step workflow: technology landscape to evidence-ranked strategies

1. 1

   Enter a technology-focused research question covering mechanisms, formulations, and the commercial landscape

   Frame the question around a specific drug-delivery technology, therapeutic modality, or platform science. Ask about mechanisms of action, recent patents or formulation strategies, and the key players involved.

   Example prompt

   "What are the current oral peptide delivery technologies, focusing on the mechanisms of absorption enhancers (such as SNAC and medium-chain fatty acids) and recent formulation patents (including strategies like pH modulation, enzyme inhibition, and nanotechnology-based carriers)?"

2. 2

   Review the initial AI synthesis as a technology landscape overview

   BioSkepsis returns a structured answer covering the underlying science (e.g., how each absorption enhancer works at the molecular level), the marketed technologies (e.g., Rybelsus/SNAC, Mycapssa/C8, GIPET/C10), and the emerging approaches (e.g., nanocarriers, robotic pills). Check the unverified citations panel for flagged references before you rely on any single number.

3. 3

   Map the competitive landscape: companies, platforms, and patent families

   Ask which companies and patent families dominate the space, and what citation clusters reveal about where innovation is converging. This produces a structured overview of key players, their proprietary platforms, and the emerging innovation hubs.

   Example prompt

   "Which companies and patent families most frequently appear in oral peptide delivery filings, and what do citation clusters reveal about emerging innovation hubs or converging formulation strategies?"

4. 4

   Assess the gap between mechanistic claims and clinical reality

   Ask how well the mechanistic claims in patents and preclinical studies hold up when tested in actual human pharmacokinetic studies. This is the critical "does it actually work?" question that separates hype from translational evidence.

   Example prompt

   "How well do the mechanistic claims in oral peptide formulation patents (e.g., permeability enhancement, enzyme inhibition) align with observed pharmacokinetic outcomes in early clinical studies?"

5. 5

   Identify recurring technical limitations and unresolved challenges

   Ask what limitations are repeatedly disclosed across patents, publications, and clinical reports. This surfaces the systemic barriers the field has not yet solved — the problems that any new entrant or investor must account for.

   Example prompt

   "What are the key technical and clinical limitations repeatedly disclosed across oral peptide delivery patents and publications, such as variability in absorption, food effects, or dose dependency?"

6. 6

   Benchmark formulation approaches by clinical evidence strength

   Ask which specific formulation strategies have the strongest clinical evidence for meaningful improvements — not just in bioavailability numbers, but in patient-relevant outcomes compared to existing therapies.

   Example prompt

   "Which formulation approaches show the strongest evidence of clinically meaningful improvements in bioavailability or patient-relevant outcomes compared with injectable peptide therapies?"

What you walk away with

• Technology landscape overview — the underlying science, the marketed technologies, and the emerging approaches, with unverified citations flagged

• Competitive & patent map — key players, proprietary platforms, recurring patent families, and the citation clusters that mark innovation hubs

• Claims-versus-reality assessment — where patent and preclinical mechanistic claims hold up against human pharmacokinetic and clinical data

• Evidence-ranked strategies — formulation approaches benchmarked by clinical-evidence strength and patient-relevant outcomes

Honest limits

• AI maps the published and patent literature — not confidential pipelines. BioSkepsis cannot reveal unpublished filings, internal R&D, or undisclosed deal terms.

• Patent-family analysis is directional, not a freedom-to-operate opinion. Use it to scope the landscape and brief counsel — get a formal FTO/patent search for licensing and clearance decisions.

• Citation flags surface likely errors, not certainty. Verify each PMID and effect size against the source before it enters a due-diligence memo.

• Final strategic judgement is human. BioSkepsis builds the evidence base; your team weighs commercial, regulatory, and IP risk.

Frequently asked

Related use cases